



SPAFID
CONNECT

| | | |
|---|---|------------|
| Informazione Regolamentata n. 20106-24-2021 | Data/Ora Ricezione 29 Aprile 2021 09:47:39 | MTA - Star |
|---|---|------------|

Societa' : Pharmanutra S.p.A.
Identificativo : 146078
Informazione
Regolamentata
Nome utilizzatore : PHARMANUTRAN02 - Lacorte Roberto
Tipologia : REGEM
Data/Ora Ricezione : 29 Aprile 2021 09:47:39
Data/Ora Inizio : 29 Aprile 2021 09:47:40
Diffusione presunta
Oggetto : PR - PHARMANUTRA Synthetic report on
voting results shareholder's meeting 26 04
2021

Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: Synthetic Report on voting results on agenda items of the Ordinary Shareholders' Meetings held on April 26, 2021

Pisa, 29th April 2021 – [PharmaNutra S.p.A.](https://www.pharmanutra.it) (MTA; Ticket PHN) informs that the Synthetic Report on voting results on agenda items of the Ordinary Shareholders' Meeting held on 26 April 2021 is available on the website at www.pharmanutra.it (section Governance/Shareholders' Meetings).

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative medical devices, handling the entire production process, from proprietary raw materials to the finished product. The effectiveness of its products is documented by considerable scientific proof, including 140 publications. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 39 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](https://www.pharmanutra.it)

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa
Tel. +39 050 7846500
investorrelation@PharmaNutra.it

Internal Press Office
press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan
Tel. +39 02 83635708

Matteo Russo
mrusso@sprianocommunication.com
Cristina Tronconi
ctronconi@sprianocommunication.com

Fine Comunicato n.20106-24

Numero di Pagine: 3